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Abstract
The composition of the vaginal microbiome, including both the presence of pathogens
involved in sexually transmitted infections (STI) as well as commensal microbiota, has been
shown to have important associations for a woman’s reproductive and general health. Cur-
rently, healthcare providers cannot offer comprehensive vaginal microbiome screening, but
are limited to the detection of individual pathogens, such as high-risk human papillomavirus
(hrHPV), the predominant cause of cervical cancer. There is no single test on the market
that combines HPV, STI, and microbiome screening. Here, we describe a novel inclusive
vaginal health assay that combines self-sampling with sequencing-based HPV detection
and genotyping, vaginal microbiome analysis, and STI-associated pathogen detection. The
assay includes genotyping and detection of 14 hrHPV types, 5 low-risk HPV types (lrHPV),
as well as the relative abundance of 31 bacterial taxa of clinical importance, including Lacto-
bacillus, Sneathia, Gardnerella, and 3 pathogens involved in STI, with high sensitivity, speci-
ficity, and reproducibility. For each of these taxa, reference ranges were determined in a
group of 50 self-reported healthy women. The HPV sequencing portion of the test was eval-
uated against the digene High-Risk HPV HC2 DNA test. For hrHPV genotyping, agreement
was 95.3% with a kappa of 0.804 (601 samples); after removal of samples in which the
digene hrHPV probe showed cross-reactivity with lrHPV types, the sensitivity and specificity
of the hrHPV genotyping assay were 94.5% and 96.6%, respectively, with a kappa of 0.841.
For lrHPV genotyping, agreement was 93.9% with a kappa of 0.788 (148 samples), while
sensitivity and specificity were 100% and 92.9%, respectively. This novel assay could be
used to complement conventional cervical cancer screening, because its self-sampling
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Introduction
A woman’s vaginal health is critical for her general well-being and reproductive success, and is
in part determined by the vaginal microbiome composition, the presence of pathogens associ-
ated with sexually transmitted infections (STI), and the presence of human papillomavirus
(HPV) types that can cause genital warts or cervical cancer. Current clinical vaginal health
assays focus on the detection of STI or that of HPV, but there is no single test that combines
these targets with vaginal microbiome analysis or with self-sampling.
The human vaginal microbiome has a unique composition compared to other microbial
communities in the human body. In most healthy women, the vaginal microbiome is charac-
terized by a low bacterial diversity and a dominance of lactobacilli, with low abundance of
other bacterial genera [1,2]. Several vaginal microbial community types have been described,
most of which are dominated by a single Lactobacillus species. Lactic acid produced by lactoba-
cilli lowers the vaginal pH, which is believed to create an environment unfavorable for the
growth of pathogenic bacteria [3]. Low numbers of vaginal lactobacilli have been associated
with many health conditions, such as bacterial vaginosis [1,4–6], aerobic vaginitis [7], cervicitis
[8], and STI [9–12]. The composition of a woman’s vaginal microbiome thus plays an impor-
tant role in women’s health and reproductive success. Yet, the analysis of this microbial com-
munity is not part of regular health care for women. In the US, as in many other countries,
most healthcare providers instead focus on the detection of high-risk human papillomavirus
(hrHPV), the predominant cause for cervical cancer.
Cervical cancer is one of the major causes of cancer-related deaths in women, with an
annual worldwide mortality of 250,000 [13,14]. hrHPV DNA can be detected in almost all
(>99%) cervical cancer specimens, and HPV is therefore considered the predominant causa-
tive agent for cervical cancer [15,16]. Although HPV infection is the most common STI world-
wide, not all HPV infections will lead to cancer. Firstly, certain HPV types have higher
oncogenic risks than others. Of the over 170 different HPV genotypes known to date, twelve
types have been classified as Group 1 human carcinogens; these include types 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, and 59 [17,18]. Together with other closely related HPV types, such as
66 and 68, which have been listed as probably or possibly carcinogenic, these are collectively
called hrHPV types. hrHPV types 16 and 18 can be found in over 70% of cervical cancers [19]
and the presence of these types is associated with the highest chance of developing cancer
within 10 years [20]. However, other hrHPV genotypes have also been shown to cause cervical
cancer, and especially among women of non-European descent [21]. In addition, many
hrHPV infections are temporary and will be cleared within months of acquisition, without
proceeding to pre-cancerous lesions [22]. Other HPV types, collectively called low-risk HPV
(lrHPV), are not implicated in cervical cancer, but instead cause genital warts [23].
National cervical cancer screening programs are offered to women worldwide with a start-
ing age between 20 and 35 years old [24]. Most of these programs involve an invitation for a
Pap smear, in which a woman’s cervical cells are obtained by a physician for cytology [25], but
additional molecular HPV testing is increasingly offered by health care providers as well [26].
In the United States, most healthcare providers follow the American College of Obstetricians
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and Gynecologists (ACOG) guidelines [27] or the U.S. Preventive Services Task Force
(USPSTF) guidelines for women [28] to come in for a Pap smear, often with HPV testing,
every three to five years, depending on age and risk factors. The most recent USPSTF guide-
lines, released in August 2018, even include HPV testing alone as a recommended option for
women over 30 [29].
Several commercial kits have FDA pre-market approval for the molecular detection of HPV
[30]. In a 2014 meta-analysis of 36 studies, the Qiagen digene Hybrid Capture 2 (HC2) assay
was the most widely used [31]. In the HC2 assay, cervical specimens are denatured with
sodium hydroxide, denatured viral DNA is hybridized with specific RNA probes, and RNA:
DNA hybrids are subsequently detected with antibodies [32]. The HC2 test detects 13 hrHPV
types, but does not report which specific type is present. Other HPV detection assays involve
the amplification of viral DNA by Polymerase Chain Reaction (PCR). The most widely used
primer pairs for HPV PCR detection are the GP5+/6+ primers [33] and the degenerate MY09/
11 primers [34] or the PGMY09/11 primer pool [35], which are all based on conserved regions
in the viral L1 open reading frame. The COBAS 4800 assay detects 14 hrHPV types using mul-
tiplex real-time PCR with specific probes; it reports the presence of HPV16, HPV18, or one of
12 remaining hrHPV types [36].
The vaginal microbiome is an emerging area of research in understanding the role of HPV
infections and reducing the risk of cervical cancer [37]. Several studies suggest a relationship
between the composition of the vaginal microbiota and the acquisition and persistence of
HPV infection. For example, vaginal microbial diversity is increased during an HPV infection,
with decreased levels of Lactobacillus species and an increased presence of other microbial
members such as Sneathia species or Gardnerella vaginalis [38–42]. In addition, certain micro-
biota compositions are associated with increased clearance of detectable HPV [40].
In this study, we tested the feasibility of a novel assay, that combines the detection and iden-
tification of HPV DNA, STI-associated pathogens, and microbiome analysis on samples
obtained through self-sampling. We validated the performance of marker gene amplification
and sequencing to detect the presence and relative abundance of 31 clinically important bacte-
rial targets with high precision and accuracy. In addition to detecting Lactobacillus, Sneathia,
and Gardnerella spp., this test detects STI-associated pathogens including Chlamydia tracho-
matis, Mycoplasma genitalium, and Neisseria gonorrhoeae, which combined infect over 150
million people each year and cause genital tract infections and cervicitis [10–12]. The perfor-
mance of a novel amplification and sequencing-based strategy for HPV detection and type-
specific identification was compared to that of the most widely used test for HPV detection in
cervicovaginal specimens, the digene HC2 test. This assay was not developed to be employed
in a clinical setting, but intended to complement, rather than replace, current healthcare
guidelines for in-clinic cervical cancer screening.
Materials and methods
Study participants and sample collection
This study was approved under a Human Subjects Protocol provided by an independent IRB
(E&I Review Services, IRB Study #13044, 05/10/2013). E&I is fully accredited by the Associa-
tion for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP), with
Registration # IRB 00007807. uBiome undergoes a yearly voluntary continuing review by E&I
Review Services to determine that the project meets the same scrutiny of human subjects pro-
tections as projects conducted at research institutions. The IRB board membership of E&I
Review Services is consistent with the Code of Federal Regulations (CFR) requirements of 21
CFR 56.107 and 45 CFR 46.107. Where required, specimens used in this study consisted of
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vaginal samples from women who had signed an informed consent to have their samples used
for research. All participants were 18 years or older.
A vaginal self-collection kit was sent to each participant’s home address, consisting of a ster-
ile swab, a tube with sterile water, a tube with zirconia beads in a proprietary lysis and stabiliza-
tion buffer that preserves the DNA for transport at ambient temperatures, and sampling
instructions (S1 Fig, included in the Supplementary Materials). Participants were instructed to
wet the swab with the sterile water, insert the swab into the vagina as far as is comfortable,
make circular movements around the swab’s axis for 1 minute (min), and then stir the swab
for 1 min into the tube with lysis buffer and beads. After shaking the tube for 1 min to homog-
enize, the tube was then shipped by the participants to the laboratory by regular mail.
For the determination of the reference ranges of the 31 bacterial targets, a set of 50 vaginal
specimens, each from a different woman (average age 48.4 ± 15.6 years; range 23 to 79 years),
was selected. Inclusion criteria were the following: completion of the voluntary health survey
that every woman was invited to participate in, and no self-report of any of the following con-
ditions: bacterial vaginosis, cervical cancer, genital herpes or warts, urinary tract infection, or
infection with HPV, C. trachomatis, T. pallidum, or yeast. In addition, all of these women
reported no antibiotic usage in the six months before sampling.
A different set of specimens from 87 women was used to compare the performance of sam-
pling with the digene collection device (Qiagen, Gaithersburg, MD, USA) and DNA extracted
from samples collected with swabs. For this subset, women were asked to self-sample 2 vaginal
specimens within 15 minutes. The first specimen was collected by using the digene collection
device, which consists of a cervical brush and a digene transport tube with Specimen Transport
Medium (STM). The second specimen was collected using a pre-wetted swab and resuspended
in a collection tube with lysis buffer and beads, as described above, and used for DNA
extraction.
For use in spiking and intra-run technical repeatability experiments described below,
homogenized “vaginal pools” were created by combining 96 vaginal samples derived from 11
or 16 individuals who sampled themselves multiple times. These pools were created to make a
relative large amount of a homogenized complex matrix similar to real biological samples. The
pool created from samples taken by 16 subjects was used to test the synthetic DNA in spiking
experiments, while the pool of samples taken by 11 subjects was used in the technical repeat-
ability experiment (see below).
An additional set of 718 vaginal specimens were selected to compare the performance of
the digene HC2 HPV test using the hrHPV probe (601 specimens) and lrHPV probe (148 spec-
imens; overlap of 31 specimens), respectively, versus that of the amplification and sequence-
based HPV type identification described in this study. Of these, 361 samples were from sub-
jects who consented, while the remaining samples were residual clinical samples that were ana-
lyzed anonymously.
Positive STI control samples
Ten de-identified cervicovaginal swab specimens of known STI pathogen status were obtained
through a commercial source (iSpecimen, Lexington, MA). Five of these samples were
reported to be positive for C. trachomatis and negative for N. gonorrhoeae, while a second set
of five samples were negative for C. trachomatis and positive for N. gonorrhoeae. Each sample
was tested in five replicates for DNA extraction, 16S rRNA gene amplification, and target iden-
tification as described below. To confirm the presence of M. genitalium in 13 samples that
tested positive and 9 samples that tested negative for this pathogen in the assay using the 16S
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rRNA gene amplification described in this study, a PCR was performed using primers on the
MgPa adhesin gene [43].
In silico 16S rRNA gene target performance metrics
The assay includes 31 bacterial targets with clinical relevance for women’s reproductive tract
health, which were identified through an exhaustive literature search (Fig 1). The most relevant
associations between health conditions and the vaginal microbiota were narrowed down by
choosing associations with high statistical significance that were found in humans subjects,
not in laboratory animals or bioreactors, but performed on case/control, cohorts or random-
ized studied population. These include bacterial vaginosis [1,4–6], aerobic vaginitis [7], pelvic
inflammatory disease [44], and sexually transmitted infections [10–12]. A complete list of
these associations and references are provided in S1 Table. For each bacterial taxon intended
to be included in this assay, using a process similar to that described in Almonacid et al. [45],
we determined in silico performance metrics for identification of each taxa (sensitivity, speci-
ficity, positive and negative predictive value). Briefly, sequences assigned to each taxon in the
SILVA database (Version 123) [46] were considered to be real positives for that taxon. Then,
assuming amplification with up to two mismatches with the primers used, we identified for
each taxa the sequences that would produce an amplicon, and evaluated whether that amplicon
is unique to the taxon of interest (ti) or also shared by sequences from different taxa (dt). The
number of true positives (TP), true negatives (TN), false positives (FP) and false negatives
(FN) was computed for different tolerance ratios for the quotient dt/ti, and subsequently in sil-
ico performance metrics were assessed. Of the 72 bacterial targets initially selected, the 31 tar-
gets selected for the assay had all four in silico performance metrics above 90% (S2 Fig; S2
Table).
In silico HPV target performance metrics
In addition to the 31 bacterial targets, hrHPV and lrHPV targets were selected for inclusion in
the assay, based on their published association with cervical cancer lesions or genital warts (Fig
1, S1 Table). HPV reference genomes were downloaded in August 2017 from the PaVE data-
base, which is a repository of curated and annotated HPV genomes [47,48]. Only revised and
recognized sequences (180 HPV genomes) were used for an in silico PCR amplification using a
set of 15 forward and 6 reverse primers (described below) targeting the L1 gene and allowing
up to 4 mismatches between primers and target sequences. Under these conditions, the L1
genes from 118 HPV genomes could be amplified in silico. Of these, 19 HPV genomes, includ-
ing 14 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and 5 lrHPV types (6,
11, 42, 43, 44) were selected based on their association with health conditions according to lit-
erature (S1 Table). In order to evaluate the performance metrics for identification of the HPV
targets, sequences of the L1 segment of HPV genomes from the NCBI database were used. The
search was filtered to sequences with length in the range 1,500–10,000 bp and with correct
assignment of the type of the HPV (4177 sequences). These sequences were amplified in silico
using the primers described below. Following these steps, we generated 161,398 amplicons.
These sequences were mapped using VSEARCH [49] at 95% of identity against an HPV ampli-
con reference database consisting of the amplicons produced by the reference genomes in
PaVE for the 19 HPV types included in our assay. The performance metrics were calculated as
described above for the 16S rRNA gene targets. Briefly, the correct assignment of an in silico
NCBI amplicon against the reference was counted as a true positive and an incorrect assign-
ment was considered as a false negative. Also, we considered as a false negative any genome
from NCBI that our primers could not amplify. According to this, the 19 HPV types obtained
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values for sensitivity, specificity, positive predictive value (PPV) and negative predictive values
(NPV) above 90% (S3 Table).
In vitro validation of bacterial targets
To test our ability to identify members of each of the 31 bacterial targets, synthetic DNAs
(sDNAs or gBlocks, Integrated DNA Technologies, Inc., Coralville, IA), were designed encom-
passing the V4 region of the 16S rRNA gene including primer regions, based on a SILVA rep-
resentative sequence, plus 75 additional bases to both the 5’ and 3’ side, with one sDNA per
target (S4 Table). The SILVA representative sequence per taxa was chosen by performing an
all-against-all sequence comparison of all sequences in a taxa, and identifying as representative
the sequence that shared the highest similarity with the largest number of sequences in the set.
To validate that each target could be detected in a vaginal swab specimen, 3 ng of each
sDNA was spiked into 500 μl aliquots of a vaginal pool, created by combining 96 vaginal speci-
mens from 16 women included in this study, and DNA was extracted from each spiked vaginal
pool (see below). Each spike-in experiment was performed in triplicate. Subsequently, bacterial
targets were detected by amplification using PCR targeting the 16S rRNA gene, sequencing,
and a bioinformatics pipeline described below. Each target included in the final panel was
detected above limit of detection (LOD) (see below) in each of the triplicate spiked-in amplifi-
cation reactions performed on the extracted DNA from the vaginal pool (not shown).
In addition, the LOD of each target in a complex background of other targets was deter-
mined according to published guidelines [50]. First, to check for potential contamination, we
calculated a limit of blank (LOB), which was calculated using a set of 77 blank wells of a
96-well PCR plate where wells of the first row and first column of the plate each contained 200
pg/μl of synthetic 16S rRNA gene DNA from different targets. The LOB was set as the average
number of reads in these blank wells (18.57 reads) plus 1.65 standard deviations (29.70 reads),
thus at 48.27 reads. To calculate the LOD of the bacterial target, pools of bacterial sDNAs were
mixed in different ratios. To create these mixes, each bacterial sDNA was randomly assigned
to one of two pools, A and B, that each contained sDNAs in equimolar amount. Each pool was
serially diluted in PCR grade water. Pool A dilutions were mixed 1:1 with undiluted Pool B
and vice versa. All pool A/B combinations were used in triplicate for DNA extraction, amplifi-
cation, and sequencing as described below. For each target, the LOD was defined as the lowest
concentration of sDNA where at least two of the three replicates contained at least 2 reads for
that target in a sample with 10,000 reads or more. Using this LOD, we calculated a lower
threshold for detection for each taxa at its LOD as the LOB (48.27) plus the standard deviation
of the taxa at LOD � 1.65. This threshold is used to correctly assign a taxa as identified in a
sample at or above its LOD.
For targets that had both a species and a genus level sDNA present in the mixed pools A
and B, a bioinformatic correction was applied. The total reads for a genus-level target for
which a species within that genus was also present in the mixed pools, was defined as the total
measured reads for the genus and subtracting all those reads corresponding to species-level
targets belonging to that genus in the same pool mix, i.e., only reads that match to a genus and
not to a species level were finally assigned to the genus.
Fig 1. The 31 bacterial targets and HPV targets covered by the assay and their associated health conditions. Dark blue dots indicate
targets positively associated with the conditions, while pink diamonds indicate inverse associations. See S1 Table in the Supplementary
Materials for more detailed information about e.g. the HPV genotypes included and a list of references.
https://doi.org/10.1371/journal.pone.0215945.g001
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In vitro validation of HPV targets
To test the ability of our assay to detect and genotype HPV targets, fragments of the L1 gene of
approximately 600 bp long were ordered for each of the representative sequences of 19 HPV
types in the PaVE database as sDNAs (gBlocks, Integrated DNA Technologies, Inc.). To repre-
sent hrHPV type 68, two sDNAs were ordered, 68a and 68b. The sequences of the 20 gBlocks
representing 19 HPV types (14 hrHPV and 5 lrHPV) are listed in S5 Table. To validate that
each target could be detected in a vaginal swab specimen, 3 ng of each HPV sDNA was spiked
into 500 μl aliquots of a vaginal pool created by combining 96 vaginal specimens from 16
women included in this study, and DNA was extracted from each spiked vaginal pool (see
below). Subsequently, the spiked HPV targets were detected by amplification using the PCR
targeting the L1 gene and bioinformatics pipeline described below. Each spike-in experiment
was performed in triplicate. Each HPV target was detected above the LOD (see below) in each
of the triplicate spiked-in amplification reactions performed on the extracted DNA from the
vaginal pool (not shown). Each target had a ratio > 0.1 for the number of HPV-assigned reads
divided by the total number of normalized reads assigned to an internal spike-in control (see
below).
To determine the LOD of HPV targets, 10-fold serial dilutions of the sDNAs representing
HPV targets were made in nuclease-free water, ranging from 105 to 102 molecules per μl. Dilu-
tions of one target were inversely combined with dilutions of another target, forming different
pairs of HPV sDNAs. Each dilution pair was used directly as template for PCR in triplicate as
described below.
DNA extraction and amplification targeting 16S rRNA and HPV L1 genes
DNA was extracted from vaginal specimens, pools thereof, or sDNA dilutions in tubes con-
taining lysis/stabilization buffer as described previously [45]. For 16S rRNA gene amplifica-
tion, extracted DNA was used as the input of a one-step PCR protocol to amplify the V4
variable region of the 16S rRNA gene. This PCR contained universal primers 515F and 806R
[45,51], both with sample-specific indices and Illumina tags. PCR was performed as described
before [45]. Following amplification, DNA was pooled by taking the same volume from each
reaction.
For HPV amplification, extracted DNA was used as the input of a PCR protocol to amplify
the HPV L1 gene. To each sample, sDNA with a randomized HPV type 16 sequence was
added as an internal positive control. The first PCR mix contained a pool of previously
described HPV specific primers [35,52], and two new primers, HPV_RSMY09-LvJJ_Forward:
5’ CGTCCTAAAGGGAATTGATC, and HPV_PGMY11-CvJJ_Reverse: 5’ CACAAGGCCAT
AATAATGG. All these primers contained sequencing adaptor regions. The PCR products from
the first amplification round were used as input for a second PCR containing sample-specific
forward and reverse indices and Illumina tags. PCR products from this second step were
pooled for sequencing.
The 16S rRNA gene and HPV PCR consolidated library pools were separately quantified by
qPCR using the KAPA Library Quant Kit (Bio-Rad iCycler qPCR Mix) following the manufac-
turer’s instructions using a BioRad MyiQ iCycler. Sequencing was performed in a paired-end
modality on the Illumina NextSeq 500 platform rendering 2 x 150 bp paired-end sequences.
Sequence analysis and taxonomic annotation for bacterial targets
After sequencing, demultiplexing of reads according to sample-specific barcodes was per-
formed using Illumina’s BCL2FASTQ algorithm. Reads were filtered using an average Q-
score > 30. Forward and reverse 16S rRNA gene reads were appended together after removal
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of primers and any leading bases, and clustered using version 2.1.5 of the Swarm algorithm
[53] using a distance of one nucleotide and the “fastidious” and “usearch-abundance” flags.
The most abundant sequence per cluster was considered the real biological sequence and was
assigned the count of all reads in the cluster. The representative reads from all clusters were
subjected to chimera removal using the VSEARCH algorithm [49]. Reads passing all above fil-
ters (filtered reads) were aligned using 100% identity over 100% of the length against the true
positive 16S rRNA gene sequences identified in silico from SILVA for each of the 31 taxonomic
groups targeted by the assay as described above (S4 Table). The relative abundance of each
taxon was determined by dividing the count linked to that taxa by the total number of filtered
reads.
Sequence analysis and taxonomic annotation for HPV targets
Raw sequencing reads were demultiplexed using BCL2FASTQ. Primers were removed using
cutadapt [54]. Trimmomatic [55] was used to remove reads with a length less than 125 bp, and
a mean quality score below 30. After that, forward and reverse paired reads were joined using
custom in-house scripts and converted to a fasta file. Identical sequences were merged and
written to a file in fasta format and sorted by decreasing abundance using—derep_fulllength
option in VSEARCH [49]. Target sequences in the fasta files were compared to the fasta-for-
matted query database sequences (19 HPV target sequences) using the global pairwise align-
ment option with VSEARCH, using 95 percent sequence identity, to obtain the counts for
each HPV type within a different sample.
The HPV portion of the assay was considered positive if the number of sequence reads
assigned to the specific HPV types was above the threshold at the limit of detection, and
greater than a previously defined cutoff. To set this cutoff, two normalization steps were
employed. First, according to in silico PCR amplification, a different number of combinations
of primers amplify different HPV targets (e.g. HPV16 is amplified using 66 different combina-
tions, while HPV43 is amplified with just 10 combinations), reflecting the sequence variability
within the primer binding site among HPVs. This also means that the spiked-in internal con-
trol and the target HPV have different amplification efficiencies. To avoid this bias, the inter-
nal control (which has the primer sites for HPV16) is normalized for the amplification factor
(number of primer combinations that generate an amplicon) of each HPV type. The number
of HPV-assigned reads was divided by the total number of normalized reads assigned to the
spike, and a sample was considered HPV-positive if that ratio was above 0.1, which corre-
sponds to approximately 500 target molecules.
Intra- and inter-run precision
Intra-run technical repeatability was assessed by including nine replicates of the same vaginal
pool (consisting of 96 vaginal samples derived from 11 individuals) into the same DNA extrac-
tion, 16S rRNA gene amplification, and sequencing run. This experiment was then repeated in
two additional sequencing runs to yield three sets of nine replicate samples analyzed within
the same run. In addition, inter-run technical reproducibility was performed by processing
three replicates of a set of 18 vaginal samples on three different days by three different opera-
tors. Samples included in the analysis were those that had at least 10,000 reads and where at
least two of the three replicates were present (11 sets).
Comparison of the results, both intra- and inter-run, were done using the raw counts of the
31 bacterial species- and genus-level targets. Data was processed using the R-package Phyloseq
[56], and visualized using Principal Coordinates Analysis (PCoA), based on a distance matrix
calculated using the Bray-Curtis method.
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digene HC2 hrHPV test on digene tubes or on extracted DNA
The digene HC2 HPV detection assay (Qiagen) was used as a reference to validate the hr- and
lrHPV portions of the assay. The High-Risk HPV Probe in the digene HC2 HPV test detects
hrHPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68, while the Low-Risk HPV
Probe in the digene test detects lrHPV types 6, 11, 42, 43, and 44. The vaginal health test
described here detects all these types plus hrHPV type 66. The digene HC2 assay is intended to
be used directly on cervical samples collected in the digene STM transport tube. In order to val-
idate the use of the digene kit on extracted vaginal DNA, we first compared the performance of
the digene HC2 assay on a set of 87 self-sampled, paired vaginal samples, i.e. a digene brush
resuspended in an STM transport tube, as well as DNA extracted from a vaginal swab resus-
pended in lysis and stabilization buffer according to the manufacturer’s instructions. Negative
and positive controls and calibrators included in the kit were processed within each 96-well
assay, and used for assay validation and cutoff, as per instructions. A specimen was considered
positive if its chemiluminescence measurement (Relative Light Units, RLU) was higher than or
equal to that of the assay’s Positive Calibrator cutoff (RLU ratio of 1 or more), as specified in
the digene HC2 assay instructions.
Sensitivity, specificity, and accuracy of the hr- and lrHPV portions of the vaginal health
assay were evaluated using the digene HC2 HPV DNA assay as the gold standard, and
extracted DNA from 601 (hrHPV) and 148 (lrHPV) vaginal swabs, respectively, as the input
for both tests. The vaginal health assay was considered to be positive for a HPV type if the
number of reads assigned to that HPV type divided by the normalized number of reads
assigned to a spiked-in control (see above) was greater than 0.1. Agreement between the two
methods was evaluated using Cohen’s kappa [57], where the level of agreement is defined by
the range: 0–0.20, poor; 0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.80, good; 0.81–1.00, very
good.
Sequence availability
Bacterial sequence reads of the 31 bacterial taxa and 19 HPV strains targeted by our assay are
available at the European Nucleotide Archive under accession number PRJEB25853 for all
human samples as well as pools of human samples reported in this article.
Results
Limit of detection of bacterial and HPV targets
The vaginal health assay described here is based on a list of 31 bacterial 16S rRNA gene targets
and 19 HPV types that were identified through an exhaustive literature search to play impor-
tant roles in health and disease of women’s reproductive tracts (Fig 1, S1 Table). For each bac-
terial target, the LOD was determined by combining different dilutions of pools of sDNAs,
followed by DNA extraction, amplification of the V4 region of the 16S rRNA gene using
broad-range primers, and sequencing (Fig 2A). The LOB was set as the average number of
reads in 77 blank wells (18.57 reads) plus 1.65 standard deviations (29.70 reads). Using this
value, we calculated the threshold of identification for each taxon as the LOB + 1.65 standard
deviations (48.27) plus the standard deviation of the taxon at LOD � 1.65. For the 31 taxa tar-
geted by the assay, the threshold related to LODs was in the range 49.0 to 59.1reads (S6 Table).
To determine the LOD for the HPV targets, different dilutions of pools of sDNAs were
mixed as done for the bacterial targets. The molecules were then amplified, sequenced, and
analyzed by the HPV bioinformatics pipeline. For all HPV targets analyzed, the threshold
related to LODs was in the range 40.8 to 224.8 reads (Fig 2B, S7 Table).
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Intra- and inter-run variability
Intra-run technical variability was evaluated in a combined set of 18 replicates of the same vag-
inal pool, each of which yielded 10,000 reads or more. Ordination plots of both genus and spe-
cies level bacterial taxa (Fig 3) showed a tight clustering of intra-run technical replicates,
indicating that within a single sequencing run, results generated by the laboratory process and
the bioinformatics analysis were consistent.
For the inter-run analysis, a total set of 11 groups of replicates (at least two samples) passed
the filtering criteria (over 10,000 reads). The PCoA visualization at genus and species level
showed a dispersion of the different samples, but with a clustering according to the respective
replicates (Fig 3). This suggests that there is limited within-sample variation when the same
samples are processed on different days by different operators.
Relative abundance of bacterial targets in healthy vaginal samples
To determine reference ranges for the 31 bacterial targets in the assay, we selected a set of 50 vagi-
nal samples from our database. These represent self-reported healthy individuals from the uBiome
microbiome research study. In addition to health status, additional selection criteria included no
usage of antibiotics six months prior, and no current urinary tract or vaginal infections, including
the presence of STDs. The 50 samples were processed with the target database, and the relative
abundance ranges for each bacterial target in the cohort are shown (Fig 4).
As expected, given the nature of the samples, Lactobacillus was the most abundant genus,
with the widest abundance distribution. At the species level, a similar distribution of the rela-
tive abundances was found, including a wide range and a high relative abundance for Lactoba-
cillus iners.
Pathogen detection
Among the 31 bacterial targets in the assay are three pathogens implicated in STI: C. trachoma-
tis, N. gonorrhoeae, and M. genitalium. The performance of the assay to detect two of these
Fig 2. Limit of detection (LOD) of sDNAs representing bacterial and viral targets in a complex background of other sDNAs. Dilutions of two pools of
sDNAs were mixed in different amounts, and microbial targets were amplified and sequenced. For each dilution and target, the relative abundance in samples
with 10,000 reads or more are shown. A. LOD of bacterial targets. LOD read thresholds are provided in S6 Table. B. LOD of HPV targets. Two different sDNAs
were used to represent hrHPV type 68. For each dilution and HPV type, the relative abundance in samples with 10,000 reads or more are shown. The LOD read
thresholds for each HPV target are provided in S7 Table.
https://doi.org/10.1371/journal.pone.0215945.g002
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pathogens was confirmed on a set of ten clinical samples available through a commercial
source, five of which were positive for C. trachomatis, and five of which were positive for N.
gonorrhoeae. A vaginal pool consisting of samples derived from 11 healthy individuals was
included as a control sample, and was found to be negative (Fig 5).
The three STI-associated targets (C. trachomatis, M. genitalium, and N. gonorrhoeae) were
not present in any of the 50 samples from the healthy subject set (see also below), nor in a set
of 87 vaginal samples used to validate the performance of the digene test on extracted DNA
(see below). Twelve of thirteen positive M. genitalium samples found in a larger set of samples
used to compare the HPV genotyping part of the assay (see below) were confirmed to be
Fig 3. Inter- and intra-run reproducibility. PCoA ordination showing clustering of inter-run (11 vaginal samples analyzed in triplicate on three independent
sequencing runs) and intra-run (18 aliquots of the same vaginal pool) data, at the genus and species taxonomic level. Shapes indicate the sequencing run, while colors
indicate sample replicates. For each category (Species and Genus) samples were processed together, sharing the same scale in the visualization.
https://doi.org/10.1371/journal.pone.0215945.g003
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positive in an M. genitalium specific adhesin PCR described by others [43], while eight out of
nine negative samples were confirmed to be negative, corresponding to a sensitivity of 92.3%
and a specificity of 88.9% (not shown).
Performance of digene HC2 HPV test on extracted DNA
In order to validate the use of the digene kit on extracted vaginal DNA, we compared the per-
formance of the digene HC2 HPV assay on a set of 87 self-obtained, paired cervicovaginal
Fig 4. Reference ranges for the bacterial targets in the assay. A set of 50 vaginal samples, each from a different woman, was selected based on the self-reported answers
given to survey questions indicating general and vaginal health. Each dot represents the relative abundance of a different bacterial target on genus level (top) or species
level (bottom) within a different vaginal sample. Boxes indicate the 25th-76th percentile, with the median indicated inside each colored box. Red lines indicate the 99%
percentile of each distribution, and are also the cutoff for the reference ranges. Not all of the taxa used in the assay were plotted, as some had no abundance values for
this healthy cohort (Papillibacter, C. trachomatis, M. mulieris, M. genitalium, N. gonorrhoeae, P. amnii), based on the exclusion criteria.
https://doi.org/10.1371/journal.pone.0215945.g004
Fig 5. Experimental validation of 16S rRNA gene sequencing for pathogen detection using verification samples. Ten de-identified clinical verification specimens
(iSpecimen) containing either C. trachomatis (n = 5) or N. gonorrhoeae (n = 5), as well as a vaginal pool (VP) constructed by combining 96 vaginal samples from 11
individuals, were tested for the presence of either pathogen using 16S rRNA gene amplification and sequencing. Five replicates of each specimen were tested. The
heatmap shows the relative abundance of the two pathogens in each replicate experiment, on a scale from light yellow (absent) to dark purple (100% relative abundance).
https://doi.org/10.1371/journal.pone.0215945.g005
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samples, i.e. a digene brush resuspended in digene STM, as well as DNA extracted from a
paired vaginal swab resuspended in lysis transport medium. Of the 87 samples, 84 showed con-
cordant results (69 were negative and 15 were positive for HPV in both tests) (Table 1). Three
sample pairs that were positive with the digene STM sample were HPV negative when the cor-
responding test was performed on extracted DNA. These three samples had an average digene
RLU ratio of 1.94, suggesting that these contained low levels of HPV (Fig 6). Agreement
between digene STM and digene DNA was of 96.6%, with a sensitivity of 83.3%, a specificity of
100%, and a Cohen’s Kappa of 0.89 ± 0.12 (Z = 8.39, p-value = 0.0001).
Performance of the hrHPV sequencing test on clinical samples
Using 601 vaginal specimens, the performance of the assay to detect hrHPV was compared to
that of the digene HC2 hrHPV assay. Of the 601 samples, 504 were negative in both tests, while
69 were positive in both tests (Table 2). Unexpectedly, three samples that were positive by
sequencing for hrHPV 66, which is not covered by the digene hrHPV probe, were still positive
in the digene assay. Ten digene-positive samples did not yield any validated hrHPV reads after
amplification and sequencing by our assay. Of these ten false negatives, six samples were found
to contain single or mixed non-high risk HPV strains by genotyping, including HPV 30, 61,
40, 42, 53, and 67. In addition, eighteen samples were negative in the digene HC2 hrHPV assay
but yielded sufficient hrHPV reads (of types 16, 31, 35, 51, 52, 56, 59, and 68b) to be identified
as positives by our genotyping assay. Thus, in comparison to the digene HC2 hrHPV test, the
hrHPV sequencing assay had a sensitivity of 87.3% and a specificity of 96.6%, with an overall
agreement of 95.3%, and a Cohen’s kappa of 0.804 ± 0.070 (Z = 19.8; p-value <0.0001). After
removal of the six samples where cross-reactivity of the digene hrHPV probe with lrHPV
sequences was suspected, the sensitivity and specificity of the hrHPV genotyping assay were
94.5% and 96.6%, respectively, with a kappa of 0.841 ± 0.065.
Good correlation was found between the number of normalized hrHPV sequencing reads
and the digene HC2 hrHPV RLU ratios, confirming that the PCR and sequencing hrHPV
assay described here can not only detect hrHPV types but also assess their relative abundance
(Fig 7A).
Performance of the lrHPV sequencing test on clinical samples
Using 148 vaginal specimens, the performance of the assay to detect lrHPV by genotyping was
compared to that of the digene HC2 lrHPV assay. Of the 148 samples, 118 were negative in
both tests, while 21 were positive in both tests (Table 3). No false negatives were found, but
nine samples that were negative in the digene lrHPV assay were found to have lrHPV
sequences by genotyping, of types 42, 43, and 44. Using the digene HC2 lrHPV test as the gold
standard, the lrHPV genotyping assay was found to have a sensitivity of 100% and a specificity
of 92.9%, with an overall agreement of 93.9%, Cohen’s kappa = 0.788 ± 0.131 (Z = 9.81, p-
value < 0.0001).
Table 1. digene HC2 High-Risk HPV assay performance on a set of 87 paired, self-collected vaginal samples. One
set of samples was collected using a digene brush resuspended in digene Specimen Transport medium (“digene STM”),
and the second set was extracted DNA from swabs suspended in tubes with lysis/stabilization buffer (“digene DNA”).
Samples were considered to be HPV positive if the RLU ratio was 1 or more, as instructed in the digene protocol.
digene STM hrHPV + digene STM hrHPV - Sum
digene DNA hrHPV + 15 0 15
digene DNA hrHPV - 3 69 72
Sum 18 69 87
https://doi.org/10.1371/journal.pone.0215945.t001
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As with the hrHPV assay, the number of normalized lrHPV sequencing reads was positively
correlated to the digene HC2 lrHPV RLU ratios, confirming that the PCR and sequencing
lrHPV assay described here can not only detect lrHPV types but also assess their relative abun-
dance (Fig 7B).
Fig 6. digene HC2 High-Risk HPV assay performance on a set of 87 paired, self-collected cervicovaginal samples. Samples were tested directly from STM tubes
or from a paired sample after DNA extraction. The purple lines show the cutoff of the digene assay (RLU ratio = 1). Three STM specimens were positive for hrHPV
with an average RLU ratio of<2 (low positive), but below RLU ratio = 1 for their corresponding extracted DNA specimen. The results for all other 84 specimens
were concordant. TN, true negative; TP, true positive; FN, false negative; FP, false positive.
https://doi.org/10.1371/journal.pone.0215945.g006
Table 2. Comparison of the vaginal health assay for the detection of genotyped hrHPV in DNA extracted from
601 vaginal samples to that of the digene HC2 hrHPV assay. The genotyping assay was considered positive if the
normalized number of reads assigned to any of the validated hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66, and 68) divided by the number of reads assigned to a spike in control was greater than 0.1. The digene test was con-
sidered positive if the measured RLU was equal to or greater than the assay’s cutoff (RLU ratio of 1 or higher), as per
the manufacturer’s instructions.







Sum 79 522 601
https://doi.org/10.1371/journal.pone.0215945.t002
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Positive clinical samples for hrHPV and lrHPV types
In the combined 718 samples used in the comparison of the vaginal health assay to the digene
HC2 HPV assay, 142 samples were found to be positive for 1 or more of the 19 HPV types. Of
these, 107 samples contained only a single HPV type, while 35 samples contained 2 or more
HPV types. Among the 100 samples that contained at least one of the 14 validated hrHPV
types, HPV types 52 (13%), 68 (13%), 59 (12%), and 16 (11%) were the most common. Within
the 60 samples positive for at least one of the 5 validated lrHPV types, HPV type 42 (43%) and
6 (30%) were the most common, while type 11 was not found (Fig 8).
Discussion
Here, we describe a novel vaginal health assay combining vaginal microbiome analysis, STI-
associated pathogen detection, and HPV detection and identification in a self-sampling for-
mat. Although each of these components have been described before, to our knowledge, this
Fig 7. Comparison of hrHPV and lrHPV amplification and genotyping to the digene HC2 HPV assay. DNA from 718 vaginal samples was extracted and tested by
PCR amplification and sequencing using HPV primers, and additionally used directly in the digene assay using the HC2 hrHPV (panel A) or lrHPV (panel B) probe
mix. For each sample, the x-axis shows the normalized ratio of reads assigned to validated HPV types over reads assigned to a spiked-in internal control, while the Y-axis
shows the digene HPV probe RLU values normalized over the assay’s cut-off RLU. The two purple lines show the cutoff for each of the assays. A. Comparison of hrHPV
test results in a subset of 601 samples. Six samples that were positive in the digene hrHPV assay and negative in the hrHPV genotyping assay, but in which lrHPV
sequences were detected by genotyping, are shown as light purple triangles. B. Comparison of lrHPV test results in a subset of 148 samples.
https://doi.org/10.1371/journal.pone.0215945.g007
Table 3. Comparison of the vaginal health assay for the detection of lrHPV in DNA extracted from 148 vaginal
samples by genotyping to that of the digene HC2 lrHPV assay. The genotyping assay was considered positive if the
normalized number of reads assigned to any of the validated lrHPV types (6, 11, 42, 43, 44) divided by the number of
reads assigned to a spike in control was greater than 0.1. The digene test was considered positive if the measured RLU
was equal to or greater than the assay’s cutoff (RLU ratio of 1 or higher), as per the manufacturer’s instructions.







Sum 21 127 148
https://doi.org/10.1371/journal.pone.0215945.t003
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assay is the first to combine all of these parts, thus offering women a unique opportunity to
gain a broad perspective into their vaginal and reproductive health.
The detection of hrHPV in combination with vaginal self-sampling has been proposed as
an effective method for cervical cancer risk screening [58]. Although the sensitivity of probe
hybridization-based hrHPV detection, such as the digene HC2 assay, in self-obtained vaginal
swabs has been found to be slightly lower than that in clinician-obtained cervical specimens,
hrHPV detection based on PCR was shown to be equally sensitive in self-sampled specimens
[31]. While the vaginal health assay described in this study is not intended to replace regular
cervical cancer screening programs, offering women the opportunity to self-collect vaginal
specimens poses fewer barriers for women to be screened, and thus could lead to increased
participation rates [59,60]. Therefore, allowing self-collection of vaginal samples for hrHPV
screening in parallel to regular screening programs, as already implemented in numerous
countries, and recommending women to seek further physician examination in case of a posi-
tive result may have a positive impact on rates of detection of cervical cancer, and potentially
save lives [58].
The vaginal health assay described here not only detects whether HPV is present in a sam-
ple, but also identifies the presence of specific type(s) by using sequencing analysis. Several
other HPV genotyping assays based on PCR and sequencing have been reported [30, 61–65].
These studies detected HPV types not found by traditional methods [62], as well as infections
with multiple types [63–65] with high sensitivity. As recommended by the VALGENT study
framework [66], we compared the performance of the HPV component of the test to that of
the widely used digene HC2 HPV assay. Because the novel test reported here is performed on
extracted DNA, we first validated the use of the digene assay on extracted DNA. The digene
Fig 8. Distribution of the 19 HPV types in this study. A set of 718 vaginal samples was tested in the HPV genotyping assay described in
this study. Of these, 142 samples were positive for at least one of the 19 HPV types validated in this study, with 100 samples positive for
hrHPV, and 60 for lrHPV. In 35 of the 142 positive samples, two or more HPV types were found. Positive samples are plotted as
percentage found in the total set of 718 samples.
https://doi.org/10.1371/journal.pone.0215945.g008
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performance on the extracted DNA was slightly less sensitive than that directly performed on
the digene STM tubes. The digene HC2 assay has been found to give discordant results in
about 8% of paired tests [67,68], where, for example, a positive sample will test negative at
retesting, most often in samples with a low RLU ratio in the positive test. A cutoff ratio of 2 or
3 instead of 1 has been proposed to serve as a better indicator for reproducible positive results
[67–70]. In our study, all specimens with RLU ratios of 2 or higher in the direct digene HC2
test on STM tubes were also correctly identified as positive when the test was performed on
extracted DNA, suggesting that the digene assay can be applied to extracted DNA as well.
Using extracted DNA from 718 vaginal specimens as the template, the performance of the
HPV genotyping parts of the vaginal health assay was compared to that of the digene HC2
HPV assay. The hrHPV genotyping assay showed good correlation with the digene assay, with
a sensitivity and specificity of 87.3% and 96.6%, respectively, and a Cohen’s kappa of 0.804.
Three samples containing hrHPV type 66 were found to be positive in both tests, even though
they are supposedly not covered by the digene assay. Among a set of ten samples that were
reported positive by the hrHPV digene assay but that did not contain hrHPV sequences as
determined by our assay, six samples were found to contain single or mixed lrHPV types,
including HPV 30, 61, 40, 42, 53, and 67. Cross-reactivity of the digene HC2 hrHPV probe mix
with lrHPV sequences has been demonstrated by several others [69,71–74]. Thus, even though
these samples had to be classified as false-negative because the digene HC2 HPV assay was
taken as the gold standard, it is likely they were actually false-positives in the digene test.
Removing these six samples from the comparison, the sensitivity and specificity of the hrHPV
genotyping assay were 94.5% and 96.6%, respectively, with a kappa of 0.841 ± 0.065. The
lrHPV genotyping assay had a sensitivity of 100% and a specificity of 92.9%, with a Cohen’s
kappa of 0.788. In addition, the two tests were in good general agreement about the relative
amount of HPV molecules detected. The specific genotyping of HPV by sequencing therefore
can detect the presence of lrHPV that are known to give false-positive results in conventional
clinical hrHPV tests. In addition, HPV genotyping provides clinicians and patients with more
detailed information about which strain(s) are present in the vagina, allowing for more precise
tracking of infection and clearance than most conventional assays [30].
Among the samples tested positive with hrHPV genotyping, HPV types 16, 52, 59, and 68
were most common. HPV types 6 and 42 were the most prevalent lrHPV types in the samples
tested in this study. Although our sample set was small (718 samples, of which 142 tested posi-
tive) and only screened for the presence of 19 HPV types, the high proportion of positive sam-
ples for types 6, 16, 52, 59 has been found by others [75,76], while the results for hrHPV type
68 appears to be unique in our dataset.
In addition to the HPV portion of the novel vaginal health assay described here, the assay
also reports the relative abundance of commensal and pathogenic bacteria in vaginal samples,
and compares these to reference ranges. Self-collection has been shown to be well-suited for
vaginal microbiome analysis as reported by Forney et al. who showed that microbial diversity
is similar between self-collected and physician collected vaginal samples [77].
Several bacteria have been associated with vaginal health conditions, such as bacterial vagi-
nosis [1,4–6], aerobic vaginitis [7], pelvic inflammatory disease [44], and sexually transmitted
infections [9–12]. The vaginal health assay described here detects the relative abundance of
bacteria positively associated with bacterial vaginosis, such as Sneathia or Gardnerella species,
as well as those negatively associated with that condition such as Lactobacillus species. In addi-
tion, it detects the presence of three common STI-associated pathogens, i.e., C. trachomatis, N.
gonorrhoeae, and M. genitalium. Of these, M. genitalium has been recently recognized as an
important pathogen implicated in pelvic inflammatory disease and infertility [12,78].
Although some early diagnostic tests have been described [79,80], very few clinicians test for
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its presence. Furthermore, the vaginal microbiota composition has been reported to be associ-
ated with the progression of HPV infection, from early states to cervical cancer [37,40]. Vagi-
nal microbiome analysis therefore not only can be used to detect STI-associated pathogens
and bacteria involved in bacterial vaginosis, but also to assess a woman’s microbiome similar-
ity to the microbiome of a group of individuals with progressed HPV infection. This brings
about the opportunity to leverage microbiome information to understand HPV infection pro-
gression and women’s susceptibility to cancer development. Future versions of this assay could
also include additional microorganisms associated with pathogenic outcomes such as Tricho-
monas vaginalis, Mycoplasma parvum, and Ureaplasma urealithicum.
In conclusion, we here present a vaginal health assay that for the first time combines the
detection of the most important bacterial and viral indicators of vaginal health and disease.
We envision that this test has the potential to provide clinicians and patients with a more com-
prehensive understanding of the vaginal microbiome, and to encourage women to take an
active role in related conversations with their doctors. We also hope that by improving accessi-
bility through self-sampling, we may encourage more women to engage with current screening
and treatment guidelines for vaginal pathogens and cervical cancer.
Supporting information
S1 Fig. Vaginal sampling instructions. Participants in this study were sent a vaginal sampling
kit containing a swab, sterile water to pre-wet the swab, a tube containing zirconia beads and a
lysis and stabilization buffer, and sampling instructions such as the one shown above. After
sampling according to the instructions, participants could ship their sample back by regular
mail.
(PDF)
S2 Fig. In silico performance metrics of the bacterial targets. Initially, 72 bacterial targets
were identified based on their association with vaginal and reproductive health, comprised of
57 species and 15 genera. The following performance metrics were evaluated based on the
number of true positives (TP), true negatives (TN), false positives (FP), and false negatives
(FN) detected in a manually curated amplicon database (described in S1 Doc in Almonacid
et al., 2017). The target performance are plotted as follows: specificity = TN / (TN + FP);
sensitivity = TP / (TP + FN); positive predictive value (PPV) = TP / (TP + FP); and negative
predictive value (NPV) = TN / (TN + FN). Based on a cutoff of 90% (red vertical line), 31/72
preliminary targets passed for each of the parameters, resulting in the accurate in silico detec-
tion of 16 bacterial species (light purple), and 15 bacterial genera (dark purple).
(PDF)
S1 Table. Assay targets and associated health conditions. List of all 31 bacterial targets and
19 HPV targets, their associations with different health conditions, and references.
(PDF)
S2 Table. In silico performance metrics for the 72 bacterial targets (genus and species
level) that were initially selected. PPV, positive predictive value; NPV, negative predictive
value. All values in the sensitivity, specificity, PPV, and NPV columns are given as percentages.
Of the 72 selected targets, 31 passed selection criteria of all values above 90%. Values below
90% are shown in red.
(PDF)
S3 Table. In silico performance metrics for the 19 HPV targets. HPV, human papillomavi-
rus; TP, true positive; FN, false negative; FP, false positive; TN, true negative; Sens, sensitivity
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(in %); Spec, specificity (in %); PPV, positive predictive value (in %); NPV, negative predictive
value (in %).
(PDF)
S4 Table. List of the 31 synthetic DNAs created to represent the bacterial targets included
in the assay. Sequences are based on the 16S rRNA gene.
(PDF)
S5 Table. List of the 20 synthetic DNA sequences representing 5 lrHPV and 14 hrHPV
types included in the assay. Because of sequence variability, hrHPV type 68 was represented
by 2 different sDNAs.
(PDF)
S6 Table. Limit of detection (LOD) assay for the bacterial targets. The table shows the low-
est dilution at which at least two of the three replicates had 2 or more reads per taxon, and the
calculated threshold for identification per taxa at the LOD in number of reads.
(PDF)
S7 Table. Limit of detection (LOD) assay for the HPV targets. The table shows the lowest
dilution at which at least two of the three replicates had 2 or more reads per HPV type, and the
calculated threshold for identification per HPV type at the LOD in number of reads.
(PDF)
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